CRNX — Crinetics Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $3.53bn
- $2.50bn
- $7.70m
Annual cashflow statement for Crinetics Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | C2023 December 31st | C2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -108 | -164 | -215 | -298 | -465 |
| Depreciation | |||||
| Non-Cash Items | 17 | 29.1 | 39.1 | 58 | 78.7 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.1 | 18.6 | 5.75 | 7.41 | 4.84 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -88.6 | -115 | -169 | -230 | -378 |
| Capital Expenditures | -0.436 | -1.66 | -4.69 | -3.84 | -5.76 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -56 | -172 | -196 | -571 | 180 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -56.5 | -174 | -200 | -575 | 174 |
| Financing Cash Flow Items | — | — | -0.541 | -15 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 253 | 122 | 391 | 1,015 | 40.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 108 | -167 | 22.2 | 210 | -164 |